WO2023197182A1 - 一种质谱流式血液肿瘤免疫分型中替代侧向散射光信号的抗体组合及应用 - Google Patents

一种质谱流式血液肿瘤免疫分型中替代侧向散射光信号的抗体组合及应用 Download PDF

Info

Publication number
WO2023197182A1
WO2023197182A1 PCT/CN2022/086449 CN2022086449W WO2023197182A1 WO 2023197182 A1 WO2023197182 A1 WO 2023197182A1 CN 2022086449 W CN2022086449 W CN 2022086449W WO 2023197182 A1 WO2023197182 A1 WO 2023197182A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
parts
mass
antibody
subpopulations
Prior art date
Application number
PCT/CN2022/086449
Other languages
English (en)
French (fr)
Inventor
林铖
仇陈盛
Original Assignee
浙江普罗亭健康科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 浙江普罗亭健康科技有限公司 filed Critical 浙江普罗亭健康科技有限公司
Publication of WO2023197182A1 publication Critical patent/WO2023197182A1/zh

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/62—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
    • G01N2015/012—Red blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1006—Investigating individual particles for cytology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1021—Measuring mass of individual particles

Definitions

  • the invention relates to the technical field of mass spectrometry flow cytometry, and specifically relates to an antibody combination and application that replaces side scattered light signals in mass spectrometry flow cytometry blood tumor immunophenotyping.
  • Multi-parameter flow cytometry uses fluorescent antibodies to detect CD molecules on the surface of bone marrow cells, such as stem/progenitor cell antigens, bone marrow cell line-related antigens, red blood cells, B cells, T cells, NK cells, megakaryocytes and other related antigens. Commonly used antibody combinations are usually three-color or four-color schemes, using three or four fluorophores to label the antibodies respectively.
  • Flow cytometry analysis of blood tumor classification is usually carried out in a gated manner, that is, in-depth differentiation of cell subpopulations step by step. For example, among T cells, CD3 is first used to distinguish T cells, and then CD4 and CD8 are used to distinguish CD3+CD4 +T cells and CD3+CD8+T cells.
  • the side scattered light (SSC) signal of the flow cytometer also plays a big role.
  • the first-level gating strategy is to use CD45 and SSC as the horizontal and vertical coordinates respectively to distinguish CD45 negative nucleated erythrocyte subpopulation, CD45dimSSC low primitive and immature cell subpopulation, CD45dimSSC high mature granulocyte subpopulation, CD45+SSC low lymphocyte subpopulation, and CD45+SSC intermediate monocyte subpopulation , and then conduct in-depth analysis of each subgroup through different antibodies.
  • Mass spectrometry flow cytometry is a new type of multi-parameter flow cytometry that uses metal-labeled antibodies with extremely low abundance in organisms such as rare earth metal elements to accurately detect the metal content on each cell through time-of-flight mass spectrometry. Due to the characteristics of mass spectrometer detection, there is almost no interference between different metal signals, and no compensation adjustment is required. Only a single tube of detection is needed to detect 43 antibodies (including CD molecules) on a single cell at the same time. It has methodological advantages for typing complex types of cells and makes up for the shortcomings of the current 4-6 color traditional flow cytometry. It has the potential to be used as a platform for immune detection of blood tumors.
  • CD45 and SSC are used for gating, which can quickly distinguish nucleated red blood cell subpopulations, primitive and immature cell subpopulations, monocyte subpopulations, lymphocyte subpopulations, and mature granulocyte subpopulations. wait. Since mass spectrometry uses mass spectrometry methodology and the cells are completely ionized, the SSC of traditional flow cytometry is not included in the detection process. When applied to blood tumors, it is impossible to perform first-level gates similar to flow cytometry. That is, the combined gate of CD45 and SSC cannot distinguish major cell subpopulations, which limits the clinical application and scientific research of mass spectrometry in the field of hematological tumors.
  • mass spectrometry flow cytometry can be better applied to the immunophenotypic detection of hematological tumors.
  • the purpose of the present invention is to provide an antibody combination and application that replaces side scattered light signals in mass spectrometry flow cytometry blood tumor immunophenotyping, so as to solve the deficiencies of the existing technology.
  • a first aspect of the present invention provides an antibody combination that replaces side scattered light signals in mass spectrometry flow cytometry blood tumor immunophenotyping.
  • the antibody combination is Lactoferrin (lactoferrin) antibody and Lysozyme (lysozyme) antibody.
  • Lactoferrin antibody and Lysozyme antibodies have metal tags respectively, and Lactoferrin antibodies and Lysozyme antibodies have different metal tags.
  • the metal tag is selected from 89Y, 115In, 139La, 141Pr, 142Nd, 143Nd, 144Nd, 145Nd, 146Nd, 147Sm, 148Nd, 149Sm, 150Nd, 151Eu, 152Sm, 153Eu, 154Sm, 155Gd, 156Gd, 157 Gd ⁇ 158Gd , 159Tb, 160Gd, 161Dy, 162Dy, 163Dy, 164Dy, 165Ho, 166Er, 167Er, 168Er, 169Tm, 170Er, 171Yb, 172Yb, 173Yb, 174Yb, 175Lu, 176Yb, 195Pt, 197Au, 19 8Pt, 209Bi.
  • the second aspect of the present invention provides the application of the above antibody combination in mass spectrometry flow cytometry hematological tumor immunophenotyping.
  • CD45 antibodies including primitive and immature cells or/and abnormal cell subpopulations, nucleated red blood cell subpopulations and lymphocyte subpopulations;
  • Lactoferrin antibodies, Lysozyme antibodies, CD45 antibodies, and other commonly used antibodies for immune typing of blood tumors are each equipped with metal tags, and each antibody carries a different metal tag.
  • the metal tag is selected from the group consisting of 89Y, 115In, 139La, 141Pr, 142Nd, 143Nd, 144Nd, 145Nd, 146Nd, 147Sm, 148Nd, 149Sm, 150Nd, 151Eu, 152Sm, 153Eu, 154Sm, 155Gd, 156Gd, 15 7Gd, 158Gd, 159Tb, 160Gd, 161Dy, 162Dy, 163Dy, 164Dy, 165Ho, 166Er, 167Er, 168Er, 169Tm, 170Er, 171Yb, 172Yb, 173Yb, 174Yb, 175Lu, 176Yb, 195Pt, 197 Au, 198Pt, 209Bi.
  • the third aspect of the present invention provides a gating method for mass spectrometry flow cytometry blood tumor immunophenotyping, which includes the following steps:
  • CD45 antibodies including primitive and immature cells or/and abnormal cell subpopulations, nucleated red blood cell subpopulations, and lymphocyte subpopulations;
  • Lactoferrin antibodies, Lysozyme antibodies, CD45 antibodies, and other commonly used antibodies for immune typing of blood tumors are each equipped with metal tags, and each antibody carries a different metal tag.
  • the metal tag is selected from 89Y, 115In, 139La, 141Pr, 142Nd, 143Nd, 144Nd, 145Nd, 146Nd, 147Sm, 148Nd, 149Sm, 150Nd, 151Eu, 152Sm, 153Eu, 154Sm, 155Gd, 156Gd, 15 7Gd, 158Gd , 159Tb, 160Gd, 161Dy, 162Dy, 163Dy, 164Dy, 165Ho, 166Er, 167Er, 168Er, 169Tm, 170Er, 171Yb, 172Yb, 173Yb, 174Yb, 175Lu, 176Yb, 195Pt, 197Au, 198 Pt,209Bi.
  • the fourth aspect of the present invention provides a mass spectrometry flow cytometry blood tumor immunophenotyping kit, which is composed of 43 kinds of monoclonal antibodies with metal labels, as shown in the following table:
  • numbers 1, 3, 12, 14, 17, 23, 26, 34, and 38 are intracellular antibodies, and the others are extracellular antibodies.
  • the fifth aspect of the present invention provides the application of the above-mentioned kit in mass spectrometry flow cytometry hematological tumor immunophenotyping.
  • the flow cytometry analysis software includes Flowjo analysis software, as follows:
  • CD45 antibodies including primitive and immature cells or/and abnormal cell subpopulations, nucleated red blood cell subpopulations and lymphocyte subpopulations;
  • the present invention provides an antibody combination that replaces the side scattered light signal in mass spectrometry flow cytometry blood tumor immunophenotyping.
  • the antibody combination composed of Lactoferrin antibody and Lysozyme antibody is used to replace the traditional flow side scatter light signal in the mass spectrometry flow.
  • the function of traditional flow cytometer to detect SSC is realized in the cytometer.
  • the combination of this antibody combination and the CD45 antibody is used in mass spectrometry flow cytometry for hematological tumor immunophenotyping, which can achieve the effect of traditional flow cytometry SSC and CD45 two-dimensional mapping. Combined with other commonly used antibodies for hematological tumor immunotyping, it can then perform blood Tumor immunophenotyping differentiates large groups of bone marrow cells and finds abnormal subpopulations.
  • the present invention provides a gating method for mass spectrometry flow cytometry blood tumor immunophenotyping.
  • the mature granulocyte subpopulation, monocyte subpopulation and other cell subpopulations are distinguished through Lactoferrin antibody and Lysozyme antibody.
  • Other cell subpopulations CD45 antibodies are then used to distinguish primitive and immature cells or/and abnormal cell subpopulations, nucleated red blood cell subpopulations, and lymphocyte subpopulations, and then other antibodies commonly used in blood tumor immunophenotyping are used to analyze the antigen expression of relevant subpopulations and judge. Whether there are abnormal expressions of antigens in relevant subgroups to achieve immunophenotyping of hematological tumors by mass spectrometry flow cytometry.
  • this invention uses Lactoferrin antibodies and Lysozyme antibodies, combined with CD45 antibodies to carry out a two-stage gating strategy, and cooperates with mass spectrometry flow cytometry to replace the traditional flow cytometry of CD45/SSC for mature granulocytes, monocytes, and nucleated cells in bone marrow.
  • the differentiation of red blood cells, lymphocytes, primitive and immature cells, abnormal cell subpopulations and other subpopulations breaks through the technical problem of mass spectrometry flow cytometry being unable to detect SSC in blood tumor cell analysis, combined with the multi-parameter and high-throughput characteristics of mass spectrometry flow cytometry , can improve the current depth of immune typing of hematological tumors, and also facilitate clinicians to analyze hematological tumors according to the traditional flow cytometry mode.
  • the present invention provides a mass spectrometry flow cytometry blood tumor immunophenotyping kit, which is composed of 43 kinds of monoclonal antibodies with metal labels.
  • the kit of the present invention breaks through the technical problem of mass spectrometry flow cytometry being unable to detect SSC in the analysis of blood tumor cells, achieves accurate typing of blood tumor cells by mass spectrometry flow cytometry, and can simultaneously detect 43 protein markers on a single blood tumor cell. Increased detection sensitivity, accuracy and economy.
  • the kit of the present invention can achieve the effect that traditional flow cytometer needs to use 8-10 tubes for detection by testing a single tube, and expands the scope and capability of blood tumor-related immune phenotype analysis without the need for single-staining controls for each channel.
  • kits of the present invention with the assistance of mass spectrometry flow cytometer, the types and properties of blood tumor cells can be quickly and accurately analyzed, and the level of positive cells can be judged, which has important guiding significance for prognosis judgment and the formulation of clinical treatment plans.
  • testing samples are saved, more markers can be detected for a single cell at the same time, and it also provides richer information for the research of blood tumors.
  • Utilizing the antibody combination, gating method and kit of the present invention facilitates the standardization, standardization, automation and intelligence of mass spectrometry for immunophenotyping of blood tumors.
  • Figure 1 is the immunophenotyping of healthy human bone marrow cells in Example 1.
  • Figure 2 shows the immunophenotyping of bone marrow cells in patients with acute lymphoblastic leukemia in Example 2.
  • Figure 3 shows the immunophenotyping of bone marrow cells in patients with acute myeloid leukemia in Example 3.
  • Figure 4 shows the immune phenotyping of bone marrow cells in patients with myelodysplastic syndrome in Example 4.
  • Figure 5 is the immune phenotyping of bone marrow cells in multiple myeloma patients in Example 5.
  • cCD3, cIgM, MPO, Lambda, Lactoferrin, Kappa, Lysozyme, CD79a, and TdT antibodies numbered 1, 3, 12, 14, 17, 23, 26, 34, and 38 are intracellular antibodies, and the others are extracellular antibodies.
  • bovine serum albumin solution including 375 to 625 parts by mass of bovine serum albumin, 15 to 25 parts by mass of sodium azide, and 75 to 125 parts by volume of phosphate buffer
  • centrifuge 500g/5min
  • aspirate 50uL blocking solution to the supernatant, and block on ice for 20 minutes.
  • the blocking solution consists of 0.5 ⁇ L human immunoglobulin solution (including 15 to 25 parts by mass of human immunoglobulin, 0.15 to 0.25 parts by mass sodium azide, 0.75 to 1.25 parts by mass) volume parts of phosphate buffer), 0.5uL mouse immunoglobulin solution (including 15 to 25 parts by mass of mouse immunoglobulin, 0.15 to 0.25 parts by mass of sodium azide, 0.75 to 1.25 parts by volume of phosphate buffer), 0.5uL rat immunoglobulin solution (including 15-25 parts by mass rat immunoglobulin, 0.15-0.25 parts by mass sodium azide, 0.75-1.25 parts by volume phosphate buffer), 0.5uL hamster immunoglobulin solution ( Including 15 to 25 parts by mass of hamster immunoglobulin, 0.15 to 0.25 parts by mass of sodium azide, 0.75 to 1.25 parts by volume of phosphate buffer) and 48uL bovine serum albumin solution (including 375 to 625 parts by mass of bovine serum albumin, Composed of 15 to 25 parts by
  • extracellular antibody mixture 0.5 ⁇ l each of the 34 extracellular antibodies in Table 1, each antibody concentration is 0.1-1 ⁇ g/ ⁇ L
  • bovine serum albumin solution including 375 to 625 parts by mass of bovine serum albumin
  • 15 to 25 parts by mass of sodium azide 75 to 125 parts by volume of phosphate buffer (33ul)
  • phosphate buffer 33ul
  • bovine serum albumin solution including 375 to 625 parts by mass of bovine serum albumin, 15 to 25 parts by mass of sodium azide, and 75 to 125 parts by volume of phosphate buffer
  • centrifuge 500g/5min
  • aspirate 1 ml of fixation-membrane-breaking solution containing 0.5 v/v ⁇ single cell indicator 191/193Ir, resuspend the cells, and incubate at 4°C overnight.
  • bovine serum albumin solution (including 375 to 625 parts by mass of bovine serum albumin, 15 to 25 parts by mass of sodium azide, and 75 to 125 parts by volume of phosphate buffer), centrifuge at 800g/5min, and aspirate.
  • the control group added 50uL fixation-permeable solution as a blank control
  • the experimental group added 50uL intracellular antibody mixture (0.5ul each of the 9 intracellular antibodies in Table 1, the concentration of each antibody was 0.1-1 ⁇ g/ ⁇ L, and bovine Serum albumin solution (including 375-625 parts by mass bovine serum albumin, 15-25 parts by mass sodium azide, 75-125 parts by volume phosphate buffer) 45.5ul), resuspend the cells and place on ice for 30 minutes.
  • bovine Serum albumin solution including 375-625 parts by mass bovine serum albumin, 15-25 parts by mass sodium azide, 75-125 parts by volume phosphate buffer
  • bovine serum albumin solution including 375 to 625 parts by mass of bovine serum albumin, 15 to 25 parts by mass of sodium azide, and 75 to 125 parts by volume of phosphate buffer
  • centrifuge at 800g/5min and aspirate. Supernatant.
  • bovine serum albumin solution including 375 to 625 parts by mass of bovine serum albumin, 15 to 25 parts by mass of sodium azide, and 75 to 125 parts by volume of phosphate buffer
  • centrifuge at 800g/5min and aspirate. Supernatant.
  • the analysis results are shown in Figure 1.
  • the lactoferrin+ and Lysozyme+ cell groups are mature granulocyte subpopulations and express mature granulocyte markers CD33, CD11b, and CD15; Lactoferrin is medium.
  • the Lysozyme+ cell population is a monocyte subpopulation and expresses monocyte markers CD14 and CD64; the cell population with low expression of Lactoferrin and Lysozyme is a nucleated red blood cell subpopulation and a lymphocyte subpopulation.
  • CD45+ lymphocytes were grouped using CD19 and CD3 to obtain CD3+CD19- T cells, CD3-CD19+ B cells, and CD3-CD19- NK cells.
  • bovine serum albumin solution including 375 to 625 parts by mass of bovine serum albumin, 15 to 25 parts by mass of sodium azide, and 75 to 125 parts by volume of phosphate buffer
  • centrifuge 500g/5min
  • aspirate 50uL blocking solution to the supernatant, and block on ice for 20 minutes.
  • the blocking solution consists of 0.5uL human immunoglobulin solution (including 15 to 25 parts by mass of human immunoglobulin, 0.15 to 0.25 parts by mass sodium azide, 0.75 to 1.25 parts by mass) volume parts of phosphate buffer), 0.5uL mouse immunoglobulin solution (including 15 to 25 parts by mass of mouse immunoglobulin, 0.15 to 0.25 parts by mass of sodium azide, 0.75 to 1.25 parts by volume of phosphate buffer), 0.5uL rat immunoglobulin solution (including 15-25 parts by mass rat immunoglobulin, 0.15-0.25 parts by mass sodium azide, 0.75-1.25 parts by volume phosphate buffer), 0.5uL hamster immunoglobulin solution ( Including 15 to 25 parts by mass of hamster immunoglobulin, 0.15 to 0.25 parts by mass of sodium azide, 0.75 to 1.25 parts by volume of phosphate buffer) and 48uL bovine serum albumin solution (including 375 to 625 parts by mass of bovine serum albumin, Composed of 15 to 25 parts by
  • extracellular antibody mixture 0.5ul each of the 34 extracellular antibodies in Table 1, each antibody concentration is 0.1-1 ⁇ g/ ⁇ L, and bovine serum albumin solution (including 375 to 625 parts by mass of bovine serum albumin) , 15 to 25 parts by mass of sodium azide, 75 to 125 parts by volume of phosphate buffer (33ul), resuspend the cells, and stain on ice for 30 minutes.
  • bovine serum albumin solution including 375 to 625 parts by mass of bovine serum albumin
  • phosphate buffer 33ul
  • bovine serum albumin solution including 375 to 625 parts by mass of bovine serum albumin, 15 to 25 parts by mass of sodium azide, and 75 to 125 parts by volume of phosphate buffer
  • centrifuge 500g/5min
  • aspirate 1 ml of fixation-membrane-breaking solution containing 0.5 v/v ⁇ single cell indicator 191/193Ir, resuspend the cells, and incubate at 4°C overnight.
  • bovine serum albumin solution (including 375 to 625 parts by mass of bovine serum albumin, 15 to 25 parts by mass of sodium azide, and 75 to 125 parts by volume of phosphate buffer), centrifuge at 800g/5min, and aspirate.
  • the control group added 50uL fixation-permeable solution as a blank control
  • the experimental group added 50uL intracellular antibody mixture (0.5ul each of the 9 intracellular antibodies in Table 1, the concentration of each antibody was 0.1-1 ⁇ g/ ⁇ L, and bovine Serum albumin solution (including 375-625 parts by mass bovine serum albumin, 15-25 parts by mass sodium azide, 75-125 parts by volume phosphate buffer) 45.5ul), resuspend the cells and place on ice for 30 minutes.
  • bovine Serum albumin solution including 375-625 parts by mass bovine serum albumin, 15-25 parts by mass sodium azide, 75-125 parts by volume phosphate buffer
  • bovine serum albumin solution including 375 to 625 parts by mass of bovine serum albumin, 15 to 25 parts by mass of sodium azide, and 75 to 125 parts by volume of phosphate buffer
  • centrifuge at 800g/5min and aspirate. Supernatant.
  • bovine serum albumin solution including 375 to 625 parts by mass of bovine serum albumin, 15 to 25 parts by mass of sodium azide, and 75 to 125 parts by volume of phosphate buffer
  • centrifuge at 800g/5min and aspirate. Supernatant.
  • the analysis results are shown in Figure 2.
  • the cell populations of lactoferrin+ and Lysozyme+ are mature granulocyte subpopulations; Lactoferrin is of medium intensity, and the cell population of Lysozyme+ is the monocyte subpopulation. group; the cell groups with low expression of Lactoferrin and Lysozyme are abnormal cell subpopulations and lymphocyte subpopulations.
  • the abnormal cells express CD34, CD117, HLA-DR, and CD19.
  • bovine serum albumin solution including 375 to 625 parts by mass of bovine serum albumin, 15 to 25 parts by mass of sodium azide, and 75 to 125 parts by volume of phosphate buffer
  • centrifuge 500g/5min
  • aspirate 50uL blocking solution to the supernatant, and block on ice for 20 minutes.
  • the blocking solution consists of 0.5uL human immunoglobulin solution (including 15 to 25 parts by mass of human immunoglobulin, 0.15 to 0.25 parts by mass sodium azide, 0.75 to 1.25 parts by mass) volume parts of phosphate buffer), 0.5uL mouse immunoglobulin solution (including 15 to 25 parts by mass of mouse immunoglobulin, 0.15 to 0.25 parts by mass of sodium azide, 0.75 to 1.25 parts by volume of phosphate buffer), 0.5uL rat immunoglobulin solution (including 15-25 parts by mass rat immunoglobulin, 0.15-0.25 parts by mass sodium azide, 0.75-1.25 parts by volume phosphate buffer), 0.5uL hamster immunoglobulin solution ( Including 15 to 25 parts by mass of hamster immunoglobulin, 0.15 to 0.25 parts by mass of sodium azide, 0.75 to 1.25 parts by volume of phosphate buffer) and 48uL bovine serum albumin solution (including 375 to 625 parts by mass of bovine serum albumin, Composed of 15 to 25 parts by
  • extracellular antibody mixture 0.5ul each of the 34 extracellular antibodies in Table 1, each antibody concentration is 0.1-1 ⁇ g/ ⁇ L, and bovine serum albumin solution (including 375 to 625 parts by mass of bovine serum albumin) , 15 to 25 parts by mass of sodium azide, 75 to 125 parts by volume of phosphate buffer (33ul), resuspend the cells, and stain on ice for 30 minutes.
  • bovine serum albumin solution including 375 to 625 parts by mass of bovine serum albumin
  • phosphate buffer 33ul
  • bovine serum albumin solution including 375 to 625 parts by mass of bovine serum albumin, 15 to 25 parts by mass of sodium azide, and 75 to 125 parts by volume of phosphate buffer
  • centrifuge 500g/5min
  • aspirate 1 ml of fixation-membrane-breaking solution containing 0.5 v/v ⁇ single cell indicator 191/193Ir, resuspend the cells, and incubate at 4°C overnight.
  • bovine serum albumin solution (including 375 to 625 parts by mass of bovine serum albumin, 15 to 25 parts by mass of sodium azide, and 75 to 125 parts by volume of phosphate buffer), centrifuge at 800g/5min, and aspirate.
  • the control group added 50uL fixation-permeable solution as a blank control
  • the experimental group added 50uL intracellular antibody mixture (0.5ul each of the 9 intracellular antibodies in Table 1, the concentration of each antibody was 0.1-1 ⁇ g/ ⁇ L, and bovine Serum albumin solution (including 375-625 parts by mass bovine serum albumin, 15-25 parts by mass sodium azide, 75-125 parts by volume phosphate buffer) 45.5ul), resuspend the cells and place on ice for 30 minutes.
  • bovine Serum albumin solution including 375-625 parts by mass bovine serum albumin, 15-25 parts by mass sodium azide, 75-125 parts by volume phosphate buffer
  • bovine serum albumin solution including 375 to 625 parts by mass of bovine serum albumin, 15 to 25 parts by mass of sodium azide, and 75 to 125 parts by volume of phosphate buffer
  • centrifuge at 800g/5min and aspirate. Supernatant.
  • bovine serum albumin solution including 375 to 625 parts by mass of bovine serum albumin, 15 to 25 parts by mass of sodium azide, and 75 to 125 parts by volume of phosphate buffer
  • centrifuge at 800g/5min and aspirate. Supernatant.
  • the analysis results are shown in Figure 3.
  • the bone marrow sample is divided into three groups.
  • the cell groups of lactoferrin+ and Lysozyme+ are mature granulocyte subpopulations; Lactoferrin is of medium intensity, and the Lysozyme+ cell group is monocyte subpopulation. group; the cell groups with low expression of Lactoferrin and Lysozyme are nucleated erythrocyte subpopulation, abnormal cell subpopulation and lymphocyte subpopulation.
  • CD45 Use CD45 to conduct next-level gates on cell populations with low expression of Lactoferrin and Lysozyme, and obtain CD45+ lymphocyte subpopulations, CD45 weakly positive abnormal cell subpopulations, and CD45 negative nucleated red blood cell subpopulations.
  • the abnormal cells express CD34, CD117, HLA-DR, CD33, CD13, and CD123.
  • bovine serum albumin solution including 375 to 625 parts by mass of bovine serum albumin, 15 to 25 parts by mass of sodium azide, and 75 to 125 parts by volume of phosphate buffer
  • centrifuge 500g/5min
  • aspirate To the supernatant, add 50uL blocking solution and block on ice for 20 minutes.
  • the blocking solution consists of 0.5uL human immunoglobulin solution (including 15 to 25 parts by mass of human immunoglobulin, 0.15 to 0.25 parts by mass sodium azide, 0.75 to 1.25 parts by mass) volume parts of phosphate buffer), 0.5uL mouse immunoglobulin solution (including 15 to 25 parts by mass of mouse immunoglobulin, 0.15 to 0.25 parts by mass of sodium azide, 0.75 to 1.25 parts by volume of phosphate buffer), 0.5uL rat immunoglobulin solution (including 15-25 parts by mass rat immunoglobulin, 0.15-0.25 parts by mass sodium azide, 0.75-1.25 parts by volume phosphate buffer), 0.5uL hamster immunoglobulin solution ( Including 15 to 25 parts by mass of hamster immunoglobulin, 0.15 to 0.25 parts by mass of sodium azide, 0.75 to 1.25 parts by volume of phosphate buffer) and 48uL bovine serum albumin solution (including 375 to 625 parts by mass of bovine serum albumin, Composed of 15 to 25 parts by
  • extracellular antibody mixture 0.5ul each of the 34 extracellular antibodies in Table 1, each antibody concentration is 0.1-1 ⁇ g/ ⁇ L, and bovine serum albumin solution (including 375 to 625 parts by mass of bovine serum albumin) , 15 to 25 parts by mass of sodium azide, 75 to 125 parts by volume of phosphate buffer (33ul), resuspend the cells, and stain on ice for 30 minutes.
  • bovine serum albumin solution including 375 to 625 parts by mass of bovine serum albumin
  • phosphate buffer 33ul
  • bovine serum albumin solution including 375 to 625 parts by mass of bovine serum albumin, 15 to 25 parts by mass of sodium azide, and 75 to 125 parts by volume of phosphate buffer
  • centrifuge 500g/5min
  • aspirate 1 ml of fixation-membrane-breaking solution containing 0.5 v/v ⁇ single cell indicator 191/193Ir, resuspend the cells, and incubate at 4°C overnight.
  • bovine serum albumin solution (including 375 to 625 parts by mass of bovine serum albumin, 15 to 25 parts by mass of sodium azide, and 75 to 125 parts by volume of phosphate buffer), centrifuge at 800g/5min, and aspirate.
  • the control group added 50uL fixation-permeable solution as a blank control
  • the experimental group added 50uL intracellular antibody mixture (0.5ul each of the 9 intracellular antibodies in Table 1, the concentration of each antibody was 0.1-1 ⁇ g/ ⁇ L, and bovine Serum albumin solution (including 375-625 parts by mass bovine serum albumin, 15-25 parts by mass sodium azide, 75-125 parts by volume phosphate buffer) 45.5ul), resuspend the cells and place on ice for 30 minutes.
  • bovine Serum albumin solution including 375-625 parts by mass bovine serum albumin, 15-25 parts by mass sodium azide, 75-125 parts by volume phosphate buffer
  • bovine serum albumin solution including 375 to 625 parts by mass of bovine serum albumin, 15 to 25 parts by mass of sodium azide, and 75 to 125 parts by volume of phosphate buffer
  • centrifuge at 800g/5min and aspirate. Supernatant.
  • bovine serum albumin solution including 375 to 625 parts by mass of bovine serum albumin, 15 to 25 parts by mass of sodium azide, and 75 to 125 parts by volume of phosphate buffer
  • centrifuge at 800g/5min and aspirate. Supernatant.
  • the analysis results are shown in Figure 4.
  • the cell groups of lactoferrin+ and Lysozyme+ are mature granulocyte subpopulations; Lactoferrin is of medium intensity, and the Lysozyme+ cell group is monocyte subpopulation. group; the cell groups with low expression of Lactoferrin and Lysozyme are abnormal cell subpopulations and lymphocyte subpopulations.
  • the abnormal cells express CD33, CD15, CD13, CD11b, CD19, and CD64.
  • bovine serum albumin solution including 375 to 625 parts by mass of bovine serum albumin, 15 to 25 parts by mass of sodium azide, and 75 to 125 parts by volume of phosphate buffer
  • centrifuge 500g/5min
  • aspirate 50uL blocking solution to the supernatant, and block on ice for 20 minutes.
  • the blocking solution consists of 0.5uL human immunoglobulin solution (including 15 to 25 parts by mass of human immunoglobulin, 0.15 to 0.25 parts by mass sodium azide, 0.75 to 1.25 parts by mass) volume parts of phosphate buffer), 0.5uL mouse immunoglobulin solution (including 15 to 25 parts by mass of mouse immunoglobulin, 0.15 to 0.25 parts by mass of sodium azide, 0.75 to 1.25 parts by volume of phosphate buffer), 0.5uL rat immunoglobulin solution (including 15-25 parts by mass rat immunoglobulin, 0.15-0.25 parts by mass sodium azide, 0.75-1.25 parts by volume phosphate buffer), 0.5uL hamster immunoglobulin solution ( Including 15 to 25 parts by mass of hamster immunoglobulin, 0.15 to 0.25 parts by mass of sodium azide, 0.75 to 1.25 parts by volume of phosphate buffer) and 48uL bovine serum albumin solution (including 375 to 625 parts by mass of bovine serum albumin, Composed of 15 to 25 parts by
  • extracellular antibody mixture 0.5ul each of the 34 extracellular antibodies in Table 1, each antibody concentration is 0.1-1 ⁇ g/ ⁇ L, and bovine serum albumin solution (including 375 to 625 parts by mass of bovine serum albumin) , 15 to 25 parts by mass of sodium azide, 75 to 125 parts by volume of phosphate buffer (33ul), resuspend the cells, and stain on ice for 30 minutes.
  • bovine serum albumin solution including 375 to 625 parts by mass of bovine serum albumin
  • phosphate buffer 33ul
  • bovine serum albumin solution including 375 to 625 parts by mass of bovine serum albumin, 15 to 25 parts by mass of sodium azide, and 75 to 125 parts by volume of phosphate buffer
  • centrifuge 500g/5min
  • aspirate 1 ml of fixation-membrane-breaking solution containing 0.5 v/v ⁇ single cell indicator 191/193Ir, resuspend the cells, and incubate at 4°C overnight.
  • bovine serum albumin solution (including 375 to 625 parts by mass of bovine serum albumin, 15 to 25 parts by mass of sodium azide, and 75 to 125 parts by volume of phosphate buffer), centrifuge at 800g/5min, and aspirate.
  • the control group added 50uL fixation-permeable solution as a blank control
  • the experimental group added 50uL intracellular antibody mixture (0.5ul each of the 9 intracellular antibodies in Table 1, the concentration of each antibody was 0.1-1 ⁇ g/ ⁇ L, and bovine Serum albumin solution (including 375-625 parts by mass bovine serum albumin, 15-25 parts by mass sodium azide, 75-125 parts by volume phosphate buffer) 45.5ul), resuspend the cells and place on ice for 30 minutes.
  • bovine Serum albumin solution including 375-625 parts by mass bovine serum albumin, 15-25 parts by mass sodium azide, 75-125 parts by volume phosphate buffer
  • bovine serum albumin solution including 375 to 625 parts by mass of bovine serum albumin, 15 to 25 parts by mass of sodium azide, and 75 to 125 parts by volume of phosphate buffer
  • centrifuge at 800g/5min and aspirate. Supernatant.
  • bovine serum albumin solution including 375 to 625 parts by mass of bovine serum albumin, 15 to 25 parts by mass of sodium azide, and 75 to 125 parts by volume of phosphate buffer, centrifuge at 800g/5min, and aspirate. Supernatant.
  • the analysis results are shown in Figure 5.
  • the cell populations of lactoferrin+ and Lysozyme+ are mature granulocyte subpopulations; Lactoferrin is of medium intensity, and the cell population of Lysozyme+ is the monocyte subpopulation. group; the cell groups with low expression of Lactoferrin and Lysozyme are abnormal cell subpopulations and lymphocyte subpopulations.
  • the abnormal cells expressed CD38, CD138, Kappa, and CD20 but were negative for CD56 and CD45.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Electrochemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

一种质谱流式血液肿瘤免疫分型中替代侧向散射光信号的抗体组合，为Lactoferrin抗体和Lysozyme抗体。一种质谱流式血液肿瘤免疫分型的圈门方法。一种质谱流式血液肿瘤免疫分型的试剂盒。首次采用Lactoferrin抗体和Lysozyme抗体，并结合CD45抗体进行两级圈门策略，配合质谱流式细胞仪，能够取代传统流式CD45/SSC对于骨髓中成熟粒细胞，单核细胞，有核红细胞，淋巴细胞，原始及幼稚细胞，异常细胞亚群等各亚群的区分，突破了质谱流式在血液肿瘤细胞分析中无法检测SSC的技术难题，结合质谱流式多参数高通量特性，能够提高目前血液肿瘤的免疫分型深度。

Description

一种质谱流式血液肿瘤免疫分型中替代侧向散射光信号的抗体组合及应用 技术领域
本发明涉及质谱流式细胞技术领域，具体涉及一种质谱流式血液肿瘤免疫分型中替代侧向散射光信号的抗体组合及应用。
背景技术
血液肿瘤的精准分型是正确选择治疗方案的前提，目前，国际上通用的是细胞形态学、免疫学、细胞遗传学和分子生物学分型，即MICM分型的方式。其中，免疫学分型的多参数流式细胞术扮演了重要的角色，该方法根据患者肿瘤细胞的免疫标识，提高了对具体的疾病类型鉴别的准确度。
多参数流式细胞术通过荧光抗体检测骨髓细胞表面的CD分子，如干/祖细胞抗原，骨髓细胞系相关抗原，红细胞、B细胞、T细胞、NK细胞、巨核细胞等相关抗原。常用的抗体组合通常是三色或者四色方案，使用三种或者四种荧光素分别标记抗体。流式分析血液肿瘤分型，通常会采用圈门的方式进行，即逐级对细胞亚群进行深入区分，比如在T细胞中，先用CD3区分T细胞，再用CD4和CD8区分CD3+CD4+T细胞和CD3+CD8+T细胞。流式细胞仪的侧向散射光(SSC)信号也发挥了很大的作用，目前对于流式检测结果的分析，第一级的圈门策略就是使用CD45和SSC分别作为横纵坐标，区分出CD45阴性的有核红细胞亚群，CD45dimSSC低的原始及幼稚细胞亚群，CD45dimSSC高的成熟粒细胞亚群，CD45+SSC低的淋巴细胞亚群，以及CD45+SSC中等水平的单核细胞亚群，再通过不同的抗体，对各个亚群进行深入分析。
为了完成血液肿瘤分型，往往需要检测30个以上的CD分子抗体以及一些其他的分型用抗体，由于目前临床常用的流式细胞仪是4-6色，也就是单次可以检测一个细胞上的4-6种蛋白质，完成30个以上抗体检测需要将一管骨髓分成8-10管样本分别染色和分析(其中一些抗体需要多次反复检测，用于确定细胞亚群)，样本用量大。流程繁琐，且无法对单个细胞进行30个蛋白以上参数的同步分析。多参数流式细胞术也常受到样本本底荧光的干扰，以 及不同荧光素之间发射波长的重叠，即使使用了滤光片，也需要进行补偿调节。
质谱流式细胞技术是一种新型的多参数流式细胞术，使用如稀土金属元素等生物体内丰度极低的金属标记抗体，通过飞行时间质谱来精确检测每个细胞上的金属含量，由于质谱仪检测的特性，不同金属信号之间几乎不存在干扰，不需要调整补偿。只需要单管检测，就能够同时在单个细胞上检测43种抗体(包含CD分子)，对于复杂类型的细胞分型具有方法学上的优势，弥补了目前4-6色传统流式的不足，具备作为血液肿瘤免疫检测平台的潜力。
传统流式在检测血液肿瘤时，使用CD45和SSC进行圈门，能够快速区分出有核红细胞亚群，原始及幼稚细胞亚群，单核细胞亚群，淋巴细胞亚群，成熟粒细胞亚群等。由于质谱流式使用的是质谱方法学，细胞被完全离子化，因此在检测的过程中不包含传统流式的SSC，在应用到血液肿瘤时，无法进行类似流式的第一级圈门，即CD45和SSC联合圈门，无法区分各大细胞亚群，限制了质谱流式在血液肿瘤领域的临床应用和科学研究，有必要开发一种抗体组合，能够替代传统的SSC，可以很好地弥补质谱流式的这个不足，更好地发挥其多参数同步检测的优势，使质谱流式能够更好地应用于血液肿瘤的免疫表型检测。
发明内容
本发明的目的是提供一种质谱流式血液肿瘤免疫分型中替代侧向散射光信号的抗体组合及应用，以解决现有技术的不足。
本发明采用以下技术方案：
本发明第一方面提供了一种质谱流式血液肿瘤免疫分型中替代侧向散射光信号的抗体组合，所述抗体组合为Lactoferrin(乳铁蛋白)抗体和Lysozyme(溶菌酶)抗体，Lactoferrin抗体和Lysozyme抗体分别带有金属标签，Lactoferrin抗体和Lysozyme抗体带有的金属标签不同。
进一步地，所述金属标签选自89Y、115In、139La、141Pr、142Nd、143Nd、144Nd、145Nd、146Nd、147Sm、148Nd、149Sm、150Nd、151Eu、152Sm、153Eu、154Sm、155Gd、156Gd、157Gd、158Gd、159Tb、160Gd、161Dy、162Dy、163Dy、164Dy、165Ho、166Er、167Er、168Er、169Tm、170Er、171Yb、172Yb、173Yb、 174Yb、175Lu、176Yb、195Pt、197Au、198Pt、209Bi。
本发明第二方面提供了上述抗体组合在质谱流式血液肿瘤免疫分型中的应用。
进一步地，包括如下步骤：
(1)通过Lactoferrin抗体和Lysozyme抗体区分成熟粒细胞亚群、单核细胞亚群和其他细胞亚群；
(2)其他细胞亚群再通过CD45抗体区分，包括原始及幼稚细胞或/和异常细胞亚群、有核红细胞亚群和淋巴细胞亚群；
(3)通过其他常用血液肿瘤免疫分型抗体对相关亚群的抗原表达进行分析，判断相关亚群的抗原是否存在异常表达；
其中，Lactoferrin抗体、Lysozyme抗体、CD45抗体、其他常用血液肿瘤免疫分型抗体分别带有金属标签，各抗体带有的金属标签不同。
更进一步地，所述金属标签选自89Y、115In、139La、141Pr、142Nd、143Nd、144Nd、145Nd、146Nd、147Sm、148Nd、149Sm、150Nd、151Eu、152Sm、153Eu、154Sm、155Gd、156Gd、157Gd、158Gd、159Tb、160Gd、161Dy、162Dy、163Dy、164Dy、165Ho、166Er、167Er、168Er、169Tm、170Er、171Yb、172Yb、173Yb、174Yb、175Lu、176Yb、195Pt、197Au、198Pt、209Bi。
本发明第三方面提供了一种质谱流式血液肿瘤免疫分型的圈门方法，包括如下步骤：
(1)通过Lactoferrin抗体和Lysozyme抗体区分成熟粒细胞亚群、单核细胞亚群和其他细胞亚群；
(2)其他细胞亚群再通过CD45抗体区分，包括原始及幼稚细胞或/和异常细胞亚群、有核红细胞亚群和和淋巴细胞亚群；
(3)通过其他常用血液肿瘤免疫分型抗体对相关亚群的抗原表达进行分析，判断相关亚群的抗原是否存在异常表达；
其中，Lactoferrin抗体、Lysozyme抗体、CD45抗体、其他常用血液肿瘤免疫分型抗体分别带有金属标签，各抗体带有的金属标签不同。
进一步地，所述金属标签选自89Y、115In、139La、141Pr、142Nd、143Nd、144Nd、145Nd、146Nd、147Sm、148Nd、149Sm、150Nd、151Eu、152Sm、153Eu、 154Sm、155Gd、156Gd、157Gd、158Gd、159Tb、160Gd、161Dy、162Dy、163Dy、164Dy、165Ho、166Er、167Er、168Er、169Tm、170Er、171Yb、172Yb、173Yb、174Yb、175Lu、176Yb、195Pt、197Au、198Pt、209Bi。
本发明第四方面提供了一种质谱流式血液肿瘤免疫分型的试剂盒，由43种带金属标签的单克隆抗体组成，具体如下表所示：
编号 抗体 金属 编号 抗体 金属
1 cCD3 89Y 23 Kappa 160Gd
2 CD3 115ln 24 CD99 161Dy
3 cIgM 139La 25 CD10 162Dy
4 CD56 141Pr 26 Lysozyme 163Dy
5 CD22 142Nd 27 CD64 164Dy
6 CD235ab 143Nd 28 CD2 165Ho
7 CD61 144Nd 29 CD117 166Er
8 CD23 145Nd 30 CD1a 167Er
9 CD5 146Nd 31 CD11c 168Er
10 CD15 147Sm 32 CD45 169Tm
11 CD33 148Nd 33 CD7 170Er
12 MPO 149Sm 34 CD79a 171Yb
13 CD14 150Nd 35 CD38 172Yb
14 Lambda 151Eu 36 CD138 173Yb
15 CD13 152Sm 37 CD20 174Yb
16 CD41 153Eu 38 TdT 175Lu
17 Lactoferrin 154Sm 39 HLA-DR 176Yb
18 CD123 155Gd 40 CD300e 195Pt
19 CD34 156Gd 41 CD4 197Au
20 CD71 157Gd 42 CD8 198pt
21 CD19 158Gd 43 CD11b 209Bi
22 CD9 159Tb - - -
其中，编号1、3、12、14、17、23、26、34、38为胞内抗体，其它为胞外抗体。
本发明第五方面提供了上述试剂盒在质谱流式血液肿瘤免疫分型中的应用。
进一步地，包括如下步骤：
(1)骨髓样本前处理，去除骨髓样本中的成熟红细胞；
(2)通过质谱流式细胞仪检测骨髓样本中43个抗体对应抗原的表达丰度；
(3)根据骨髓样本中43个抗体对应抗原的表达丰度，用流式细胞分析软件进行分析，所述流式细胞分析软件包括Flowjo分析软件，具体如下：
(3.1)通过Lactoferrin抗体和Lysozyme抗体区分成熟粒细胞亚群、单核细胞亚群和其他细胞亚群；
(3.2)其他细胞亚群再通过CD45抗体区分，包括原始及幼稚细胞或/和异常细胞亚群、有核红细胞亚群和淋巴细胞亚群；
(3.3)通过其余抗体对相关亚群的抗原表达进行分析，判断相关亚群的抗原是否存在异常表达。
本发明的有益效果：
1、本发明提供了一种质谱流式血液肿瘤免疫分型中替代侧向散射光信号的抗体组合，利用Lactoferrin抗体和Lysozyme抗体组成的抗体组合替代传统流式侧向散射光信号，在质谱流式细胞仪中实现了传统流式细胞仪检测SSC的功能。该抗体组合和CD45抗体结合应用于质谱流式对血液肿瘤免疫分型中，可以实现传统流式SSC和CD45二维作图的效果，再结合其他血液肿瘤免疫分型常用抗体，进而能够进行血液肿瘤免疫分型，对骨髓细胞进行大群区分，并且发现异常亚群。
2、本发明提供了一种质谱流式血液肿瘤免疫分型的圈门方法，先通过Lactoferrin抗体和Lysozyme抗体区分成熟粒细胞亚群、单核细胞亚群和其他细胞亚群，其他细胞亚群再通过CD45抗体区分原始及幼稚细胞或/和异常细胞亚群、有核红细胞亚群、淋巴细胞亚群，后通过血液肿瘤免疫分型常用的其他抗体对相关亚群的抗原表达进行分析，判断相关亚群的抗原是否存在异常表达，实现质谱流式对血液肿瘤的免疫分型。本发明首次采用Lactoferrin抗体和Lysozyme抗体，并结合CD45抗体进行两级圈门策略，配合质谱流式细胞仪，能够取代传 统流式的CD45/SSC对于骨髓中成熟粒细胞，单核细胞，有核红细胞，淋巴细胞，原始及幼稚细胞，异常细胞亚群等各亚群的区分，突破了质谱流式在血液肿瘤细胞分析中无法检测SSC的技术难题，结合质谱流式多参数高通量的特性，能够提高目前血液肿瘤的免疫分型深度，也便于临床医生按照传统流式模式对血液肿瘤进行分析。
3、本发明提供了一种质谱流式血液肿瘤免疫分型的试剂盒，由43种带金属标签的单克隆抗体组成。本发明试剂盒突破了质谱流式在血液肿瘤细胞分析中无法检测SSC的技术难题，实现质谱流式对血液肿瘤细胞的精准分型，能够在单个血液肿瘤细胞上同时检测43个蛋白标志物，增加了检测的灵敏度、准确性和经济性。本发明试剂盒经测试单管检测即可实现传统流式细胞仪需要使用8-10管检测才能实现的效果，扩大了血液肿瘤相关免疫表型分析的范围和能力，无需各通道单染对照，无需调节荧光补偿，减少了实验操作步骤及样本量需求，为进一步实现血液肿瘤免疫分型的智能化和自动化奠定基础。利用本发明试剂盒，并借助质谱流式细胞仪的辅助，可快速准确地分析血液肿瘤细胞的种类、性质、判断阳性细胞的水平，对预后判断和临床治疗方案的制定具有重要的指导意义。同时节约了检测样本，对单个细胞能够同时检出更多的标志物，也为血液肿瘤的研究工作提供了更丰富的资料。
4、利用本发明的抗体组合、圈门方法及试剂盒，利于质谱流式应用于血液肿瘤免疫分型的标准化、规范化、自动化及智能化。
附图说明
图1为实施例1健康人骨髓细胞免疫分型。
图2为实施例2急性淋巴细胞白血病患者骨髓细胞免疫分型。
图3为实施例3急性髓系白血病患者骨髓细胞免疫分型。
图4为实施例4骨髓增生异常综合征患者骨髓细胞免疫分型。
图5为实施例5多发性骨髓瘤患者骨髓细胞免疫分型。
具体实施方式
下面结合实施例和附图对本发明做更进一步地解释。下列实施例仅用于说明本发明，但并不用来限定本发明的实施范围。
以下实施例涉及的抗体如表1所示：
表1
Figure PCTCN2022086449-appb-000001
其中，编号1、3、12、14、17、23、26、34、38的cCD3、cIgM、MPO、Lambda、Lactoferrin、Kappa、Lysozyme、CD79a、TdT抗体为胞内抗体，其它为胞外抗体。
实施例1健康人骨髓细胞免疫分型
1)、准备新鲜健康人的骨髓，去除成熟红细胞。
2)、取1-3x10^6个细胞，用PBS重悬，调节体积至1mL，加入50ul-1mL 194Pt(0.1-1μM)，室温染色2min，区分细胞死活。
3)、加入2mL牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)，500g/5min离心，吸除上清，加入50uL封闭液，冰上封闭20min，其中，封闭液由0.5μL人免疫球蛋白溶液(包括15～25质量份人免疫球蛋白、0.15～0.25质量份叠氮化钠、0.75～1.25体积份磷酸盐缓冲液)、0.5uL小鼠免疫球蛋白溶液(包括15～25质量份小鼠免疫球蛋白、0.15～0.25质量份叠氮化钠、0.75～1.25体积份磷酸盐缓冲液)、0.5uL大鼠免疫球蛋白溶液(包括15～25质量份大鼠免疫球蛋白、0.15～0.25质量份叠氮化钠、0.75～1.25体积份磷酸盐缓冲液)、0.5uL仓鼠免疫球蛋白溶液(包括15～25质量份仓鼠免疫球蛋白、0.15～0.25质量份叠氮化钠、0.75～1.25体积份磷酸盐缓冲液)和48uL牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)组成。
4)、加入50uL胞外抗体混合液(表1中34种胞外抗体各0.5μl，各抗体浓度为0.1-1μg/μL，及牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)33ul)，重悬细胞，冰上染色30min。
5)、加入2mL牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)，500g/5min离心，吸除上清，加入含有0.5v/v‰单细胞指示剂191/193Ir的固定-破膜溶液1ml，重悬细胞，4℃过夜。
6)、加入2mL牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)，800g/5min离心，吸除上清；对照组加入50uL固定-破膜溶液作为空白对照，实验组加入50uL胞内抗体 混合液(表1中9种胞内抗体各0.5ul，各抗体浓度为0.1-1μg/μL，及牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)45.5ul)，重悬细胞，冰上放置30min。
7)、加入2mL牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)，800g/5min离心，吸除上清。
8)、加入2mL牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)，800g/5min离心，吸除上清。
9)、加入2mL去离子水，800g/5min离心，吸除上清。
10)、加入2mL去离子水，800g/5min离心，吸除上清。
11)、样品过滤，细胞计数，调整体积，准备上机，进行质谱流式检测。
分析结果如图1所示，使用lysozyme和Lactoferrin作图，该骨髓样本分为三群，其中lactoferrin+和Lysozyme+的细胞群为成熟粒细胞亚群，表达成熟粒细胞标志CD33，CD11b，CD15；Lactoferrin中等强度，Lysozyme+的细胞群为单核细胞亚群，表达单核细胞标志CD14，CD64；Lactoferrin和Lysozyme低表达的细胞群为有核红细胞亚群和淋巴细胞亚群。使用CD45对Lactoferrin和Lysozyme低表达的细胞群进行下一级圈门，得到CD45+的淋巴细胞亚群和CD45-的有核红细胞亚群。使用CD19和CD3对CD45+淋巴细胞进行分群，得到CD3+CD19-的T细胞，CD3-CD19+的B细胞，以及CD3-CD19-的NK细胞。
实施例2急性淋巴细胞白血病患者骨髓细胞免疫分型
1)、准备新鲜急性淋巴细胞白血病患者的骨髓，去除成熟红细胞。
2)、取1-3x10^6个细胞，用PBS重悬，调节体积至1mL，加入50ul-1mL 194Pt(0.1-1μM)，室温染色2min，区分细胞死活。
3)、加入2mL牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)，500g/5min离心，吸除上清，加入50uL封闭液，冰上封闭20min，其中，封闭液由0.5uL人免疫球蛋白溶液(包括15～25质量份人免疫球蛋白、0.15～0.25质量份叠氮化钠、0.75～1.25体积份磷酸盐缓冲液)、0.5uL小鼠免疫球蛋白溶液(包括15～25质量份小鼠免 疫球蛋白、0.15～0.25质量份叠氮化钠、0.75～1.25体积份磷酸盐缓冲液)、0.5uL大鼠免疫球蛋白溶液(包括15～25质量份大鼠免疫球蛋白、0.15～0.25质量份叠氮化钠、0.75～1.25体积份磷酸盐缓冲液)、0.5uL仓鼠免疫球蛋白溶液(包括15～25质量份仓鼠免疫球蛋白、0.15～0.25质量份叠氮化钠、0.75～1.25体积份磷酸盐缓冲液)和48uL牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)组成。
4)、加入50uL胞外抗体混合液(表1中34种胞外抗体各0.5ul，各抗体浓度为0.1-1μg/μL，及牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)33ul)，重悬细胞，冰上染色30min。
5)、加入2mL牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)，500g/5min离心，吸除上清，加入含有0.5v/v‰单细胞指示剂191/193Ir的固定-破膜溶液1ml，重悬细胞，4℃过夜。
6)、加入2mL牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)，800g/5min离心，吸除上清；对照组加入50uL固定-破膜溶液作为空白对照，实验组加入50uL胞内抗体混合液(表1中9种胞内抗体各0.5ul，各抗体浓度为0.1-1μg/μL，及牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)45.5ul)，重悬细胞，冰上放置30min。
7)、加入2mL牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)，800g/5min离心，吸除上清。
8)、加入2mL牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)，800g/5min离心，吸除上清。
9)、加入2mL去离子水，800g/5min离心，吸除上清。
10)、加入2mL去离子水，800g/5min离心，吸除上清。
11)、样品过滤，细胞计数，调整体积，准备上机，进行质谱流式检测。
分析结果如图2所示，使用lysozyme和Lactoferrin作图，该骨髓样本分为三群，其中lactoferrin+和Lysozyme+的细胞群为成熟粒细胞亚群；Lactoferrin中等强度，Lysozyme+的细胞群为单核细胞亚群；Lactoferrin和Lysozyme低表达的细胞群为异常细胞亚群和淋巴细胞亚群。使用CD45对Lactoferrin和Lysozyme低表达的细胞群进行下一级圈门，得到CD45+的淋巴细胞亚群、CD45弱阳性的异常细胞亚群。该异常细胞表达CD34，CD117，HLA-DR，CD19。
实施例3急性髓系白血病患者骨髓细胞免疫分型
1)、准备新鲜急性髓系白血病患者的骨髓，去除成熟红细胞。
2)、取1-3x10^6个细胞，用PBS重悬，调节体积至1mL，加入50ul-1mL 194Pt(0.1-1μM)，室温染色2min，区分细胞死活。
3)、加入2mL牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)，500g/5min离心，吸除上清，加入50uL封闭液，冰上封闭20min，其中，封闭液由0.5uL人免疫球蛋白溶液(包括15～25质量份人免疫球蛋白、0.15～0.25质量份叠氮化钠、0.75～1.25体积份磷酸盐缓冲液)、0.5uL小鼠免疫球蛋白溶液(包括15～25质量份小鼠免疫球蛋白、0.15～0.25质量份叠氮化钠、0.75～1.25体积份磷酸盐缓冲液)、0.5uL大鼠免疫球蛋白溶液(包括15～25质量份大鼠免疫球蛋白、0.15～0.25质量份叠氮化钠、0.75～1.25体积份磷酸盐缓冲液)、0.5uL仓鼠免疫球蛋白溶液(包括15～25质量份仓鼠免疫球蛋白、0.15～0.25质量份叠氮化钠、0.75～1.25体积份磷酸盐缓冲液)和48uL牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)组成。
4)、加入50uL胞外抗体混合液(表1中34种胞外抗体各0.5ul，各抗体浓度为0.1-1μg/μL，及牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)33ul)，重悬细胞，冰上染色30min。
5)、加入2mL牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)，500g/5min离心，吸除上清，加入含有0.5v/v‰单细胞指示剂191/193Ir的固定-破膜溶液1ml，重悬细胞，4℃过夜。
6)、加入2mL牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)，800g/5min离心，吸除上清；对照组加入50uL固定-破膜溶液作为空白对照，实验组加入50uL胞内抗体混合液(表1中9种胞内抗体各0.5ul，各抗体浓度为0.1-1μg/μL，及牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)45.5ul)，重悬细胞，冰上放置30min。
7)、加入2mL牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)，800g/5min离心，吸除上清。
8)、加入2mL牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)，800g/5min离心，吸除上清。
9)、加入2mL去离子水，800g/5min离心，吸除上清。
10)、加入2mL去离子水，800g/5min离心，吸除上清。
11)、样品过滤，细胞计数，调整体积，准备上机，进行质谱流式检测。
分析结果如图3所示，使用lysozyme和Lactoferrin作图，该骨髓样本分为三群，其中lactoferrin+和Lysozyme+的细胞群为成熟粒细胞亚群；Lactoferrin中等强度，Lysozyme+的细胞群为单核细胞亚群；Lactoferrin和Lysozyme低表达的细胞群为有核红细胞亚群、异常细胞亚群和淋巴细胞亚群。使用CD45对Lactoferrin和Lysozyme低表达的细胞群进行下一级圈门，得到CD45+的淋巴细胞亚群、CD45弱阳性的异常细胞亚群以及CD45阴性的有核红细胞亚群。该异常细胞表达CD34，CD117，HLA-DR，CD33，CD13，CD123。
实施例4骨髓增生异常综合征(MDS)患者骨髓细胞免疫分型
1)、准备新鲜骨髓增生异常综合征患者的骨髓，去除成熟红细胞。
2)、取1-3x10^6个细胞，用PBS重悬，调节体积至1mL，加入50ul-1mL 194Pt(0.1-1μM)，室温染色2min，区分细胞死活。
3)、加入2mL牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)，500g/5min离心，吸除上清，加入50uL封闭液，冰上封闭20min，其中，封闭液由0.5uL人免疫球蛋白 溶液(包括15～25质量份人免疫球蛋白、0.15～0.25质量份叠氮化钠、0.75～1.25体积份磷酸盐缓冲液)、0.5uL小鼠免疫球蛋白溶液(包括15～25质量份小鼠免疫球蛋白、0.15～0.25质量份叠氮化钠、0.75～1.25体积份磷酸盐缓冲液)、0.5uL大鼠免疫球蛋白溶液(包括15～25质量份大鼠免疫球蛋白、0.15～0.25质量份叠氮化钠、0.75～1.25体积份磷酸盐缓冲液)、0.5uL仓鼠免疫球蛋白溶液(包括15～25质量份仓鼠免疫球蛋白、0.15～0.25质量份叠氮化钠、0.75～1.25体积份磷酸盐缓冲液)和48uL牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)组成。
4)、加入50uL胞外抗体混合液(表1中34种胞外抗体各0.5ul，各抗体浓度为0.1-1μg/μL，及牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)33ul)，重悬细胞，冰上染色30min。
5)、加入2mL牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)，500g/5min离心，吸除上清，加入含有0.5v/v‰单细胞指示剂191/193Ir的固定-破膜溶液1ml，重悬细胞，4℃过夜。
6)、加入2mL牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)，800g/5min离心，吸除上清；对照组加入50uL固定-破膜溶液作为空白对照，实验组加入50uL胞内抗体混合液(表1中9种胞内抗体各0.5ul，各抗体浓度为0.1-1μg/μL，及牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)45.5ul)，重悬细胞，冰上放置30min。
7)、加入2mL牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)，800g/5min离心，吸除上清。
8)、加入2mL牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)，800g/5min离心，吸除上清。
9)、加入2mL去离子水，800g/5min离心，吸除上清。
10)、加入2mL去离子水，800g/5min离心，吸除上清。
11)、样品过滤，细胞计数，调整体积，准备上机，进行质谱流式检测。
分析结果如图4所示，使用lysozyme和Lactoferrin作图，该骨髓样本分为三群，其中lactoferrin+和Lysozyme+的细胞群为成熟粒细胞亚群；Lactoferrin中等强度，Lysozyme+的细胞群为单核细胞亚群；Lactoferrin和Lysozyme低表达的细胞群为异常细胞亚群和淋巴细胞亚群。使用CD45对Lactoferrin和Lysozyme低表达的细胞群进行下一级圈门，得到CD45+的淋巴细胞亚群、CD45弱阳性的异常细胞亚群。该异常细胞表达CD33，CD15，CD13，CD11b，CD19，CD64。
实施例5多发性骨髓瘤患者骨髓细胞免疫分型
1)、准备新鲜多发性骨髓瘤患者的骨髓，去除成熟红细胞。
2)、取1-3x10^6个细胞，用PBS重悬，调节体积至1mL，加入50ul-1mL 194Pt(0.1-1μM)，室温染色2min，区分细胞死活。
3)、加入2mL牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)，500g/5min离心，吸除上清，加入50uL封闭液，冰上封闭20min，其中，封闭液由0.5uL人免疫球蛋白溶液(包括15～25质量份人免疫球蛋白、0.15～0.25质量份叠氮化钠、0.75～1.25体积份磷酸盐缓冲液)、0.5uL小鼠免疫球蛋白溶液(包括15～25质量份小鼠免疫球蛋白、0.15～0.25质量份叠氮化钠、0.75～1.25体积份磷酸盐缓冲液)、0.5uL大鼠免疫球蛋白溶液(包括15～25质量份大鼠免疫球蛋白、0.15～0.25质量份叠氮化钠、0.75～1.25体积份磷酸盐缓冲液)、0.5uL仓鼠免疫球蛋白溶液(包括15～25质量份仓鼠免疫球蛋白、0.15～0.25质量份叠氮化钠、0.75～1.25体积份磷酸盐缓冲液)和48uL牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)组成。
4)、加入50uL胞外抗体混合液(表1中34种胞外抗体各0.5ul，各抗体浓度为0.1-1μg/μL，及牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)33ul)，重悬细胞，冰上染色30min。
5)、加入2mL牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)，500g/5min离心，吸 除上清，加入含有0.5v/v‰单细胞指示剂191/193Ir的固定-破膜溶液1ml，重悬细胞，4℃过夜。
6)、加入2mL牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)，800g/5min离心，吸除上清；对照组加入50uL固定-破膜溶液作为空白对照，实验组加入50uL胞内抗体混合液(表1中9种胞内抗体各0.5ul，各抗体浓度为0.1-1μg/μL，及牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)45.5ul)，重悬细胞，冰上放置30min。
7)、加入2mL牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)，800g/5min离心，吸除上清。
8)、加入2mL牛血清白蛋白溶液(包括375～625质量份牛血清白蛋白、15～25质量份叠氮化钠、75～125体积份磷酸盐缓冲液)，800g/5min离心，吸除上清。
9)、加入2mL去离子水，800g/5min离心，吸除上清。
10)、加入2mL去离子水，800g/5min离心，吸除上清。
11)、样品过滤，细胞计数，调整体积，准备上机，进行质谱流式检测。
分析结果如图5所示，使用lysozyme和Lactoferrin作图，该骨髓样本分为三群，其中lactoferrin+和Lysozyme+的细胞群为成熟粒细胞亚群；Lactoferrin中等强度，Lysozyme+的细胞群为单核细胞亚群；Lactoferrin和Lysozyme低表达的细胞群为异常细胞亚群和淋巴细胞亚群。使用CD45对Lactoferrin和Lysozyme低表达的细胞群进行下一级圈门，得到CD45+的淋巴细胞亚群、CD45阴性的异常细胞亚群。该异常细胞表达CD38，CD138，Kappa，CD20；而CD56，CD45阴性。

Claims (10)

  1. 一种质谱流式血液肿瘤免疫分型中替代侧向散射光信号的抗体组合，其特征在于，所述抗体组合为Lactoferrin抗体和Lysozyme抗体，Lactoferrin抗体和Lysozyme抗体分别带有金属标签，Lactoferrin抗体和Lysozyme抗体带有的金属标签不同。
  2. 根据权利要求1所述的质谱流式血液肿瘤免疫分型中替代侧向散射光信号的抗体组合，其特征在于，所述金属标签选自89Y、115In、139La、141Pr、142Nd、143Nd、144Nd、145Nd、146Nd、147Sm、148Nd、149Sm、150Nd、151Eu、152Sm、153Eu、154Sm、155Gd、156Gd、157Gd、158Gd、159Tb、160Gd、161Dy、162Dy、163Dy、164Dy、165Ho、166Er、167Er、168Er、169Tm、170Er、171Yb、172Yb、173Yb、174Yb、175Lu、176Yb、195Pt、197Au、198Pt、209Bi。
  3. 权利要求1或2所述的抗体组合在质谱流式血液肿瘤免疫分型中的应用。
  4. 根据权利要求3所述的应用，其特征在于，包括如下步骤：
    (1)通过Lactoferrin抗体和Lysozyme抗体区分成熟粒细胞亚群、单核细胞亚群和其他细胞亚群；
    (2)其他细胞亚群再通过CD45抗体区分，包括原始及幼稚细胞或/和异常细胞亚群、有核红细胞亚群和淋巴细胞亚群；
    (3)通过其他常用血液肿瘤免疫分型抗体对相关亚群的抗原表达进行分析，判断相关亚群的抗原是否存在异常表达；
    其中，Lactoferrin抗体、Lysozyme抗体、CD45抗体、其他常用血液肿瘤免疫分型抗体分别带有金属标签，各抗体带有的金属标签不同。
  5. 根据权利要求4所述的应用，其特征在于，所述金属标签选自89Y、115In、139La、141Pr、142Nd、143Nd、144Nd、145Nd、146Nd、147Sm、148Nd、149Sm、150Nd、151Eu、152Sm、153Eu、154Sm、155Gd、156Gd、157Gd、158Gd、159Tb、160Gd、161Dy、162Dy、163Dy、164Dy、165Ho、166Er、167Er、168Er、169Tm、170Er、171Yb、172Yb、173Yb、174Yb、175Lu、176Yb、195Pt、197Au、198Pt、209Bi。
  6. 一种质谱流式血液肿瘤免疫分型的圈门方法，其特征在于，包括如下步骤：
    (1)通过Lactoferrin抗体和Lysozyme抗体区分成熟粒细胞亚群、单核细胞亚 群和其他细胞亚群；
    (2)其他细胞亚群再通过CD45抗体区分，包括原始及幼稚细胞或/和异常细胞亚群、有核红细胞亚群和淋巴细胞亚群；
    (3)通过其他常用血液肿瘤免疫分型抗体对相关亚群的抗原表达进行分析，判断相关亚群的抗原是否存在异常表达；
    其中，Lactoferrin抗体、Lysozyme抗体、CD45抗体、其他常用血液肿瘤免疫分型抗体分别带有金属标签，各抗体带有的金属标签不同。
  7. 根据权利要求6所述的质谱流式血液肿瘤免疫分型的圈门方法，其特征在于，所述金属标签选自89Y、115In、139La、141Pr、142Nd、143Nd、144Nd、145Nd、146Nd、147Sm、148Nd、149Sm、150Nd、151Eu、152Sm、153Eu、154Sm、155Gd、156Gd、157Gd、158Gd、159Tb、160Gd、161Dy、162Dy、163Dy、164Dy、165Ho、166Er、167Er、168Er、169Tm、170Er、171Yb、172Yb、173Yb、174Yb、175Lu、176Yb、195Pt、197Au、198Pt、209Bi。
  8. 一种质谱流式血液肿瘤免疫分型的试剂盒，其特征在于，由43种带金属标签的单克隆抗体组成，具体如下表所示：
    编号 抗体 金属 编号 抗体 金属 1 cCD3 89Y 23 Kappa 160Gd 2 CD3 115ln 24 CD99 161Dy 3 cIgM 139La 25 CD10 162Dy 4 CD56 141Pr 26 Lysozyme 163Dy 5 CD22 142Nd 27 CD64 164Dy 6 CD235ab 143Nd 28 CD2 165Ho 7 CD61 144Nd 29 CD117 166Er 8 CD23 145Nd 30 CD1a 167Er 9 CD5 146Nd 31 CD11c 168Er 10 CD15 147Sm 32 CD45 169Tm 11 CD33 148Nd 33 CD7 170Er 12 MPO 149Sm 34 CD79a 171Yb
    13 CD14 150Nd 35 CD38 172Yb 14 Lambda 151Eu 36 CD138 173Yb 15 CD13 152Sm 37 CD20 174Yb 16 CD41 153Eu 38 TdT 175Lu 17 Lactoferrin 154Sm 39 HLA-DR 176Yb 18 CD123 155Gd 40 CD300e 195Pt 19 CD34 156Gd 41 CD4 197Au 20 CD71 157Gd 42 CD8 198pt 21 CD19 158Gd 43 CD11b 209Bi 22 CD9 159Tb - - -
    其中，编号1、3、12、14、17、23、26、34、38为胞内抗体，其它为胞外抗体。
  9. 权利要求8所述的试剂盒在质谱流式血液肿瘤免疫分型中的应用。
  10. 根据权利要求9所述的应用，其特征在于，包括如下步骤：
    (1)骨髓样本前处理，去除骨髓样本中的成熟红细胞；
    (2)通过质谱流式细胞仪检测骨髓样本中43个抗体对应抗原的表达丰度；
    (3)根据骨髓样本中43个抗体对应抗原的表达丰度，用流式细胞分析软件进行分析，所述流式细胞分析软件包括Flowjo分析软件，具体如下：
    (3.1)通过Lactoferrin抗体和Lysozyme抗体区分成熟粒细胞亚群、单核细胞亚群和其他细胞亚群；
    (3.2)其他细胞亚群再通过CD45抗体区分，包括原始及幼稚细胞或/和异常细胞亚群、有核红细胞亚群和淋巴细胞亚群；
    (3.3)通过其余抗体对相关亚群的抗原表达进行分析，判断相关亚群的抗原是否存在异常表达。
PCT/CN2022/086449 2022-04-11 2022-04-12 一种质谱流式血液肿瘤免疫分型中替代侧向散射光信号的抗体组合及应用 WO2023197182A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210375754.XA CN114720358B (zh) 2022-04-11 2022-04-11 一种质谱流式血液肿瘤免疫分型中替代侧向散射光信号的抗体组合及应用
CN202210375754.X 2022-04-11

Publications (1)

Publication Number Publication Date
WO2023197182A1 true WO2023197182A1 (zh) 2023-10-19

Family

ID=82244741

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/086449 WO2023197182A1 (zh) 2022-04-11 2022-04-12 一种质谱流式血液肿瘤免疫分型中替代侧向散射光信号的抗体组合及应用

Country Status (5)

Country Link
US (1) US20230324395A1 (zh)
EP (1) EP4261220A1 (zh)
JP (1) JP7388787B2 (zh)
CN (1) CN114720358B (zh)
WO (1) WO2023197182A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117191515A (zh) * 2023-09-08 2023-12-08 四川大学华西医院 一种肺癌肿瘤浸润淋巴细胞亚群的检测方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0181851A1 (fr) * 1984-10-10 1986-05-21 S.A. Laboratoires S.M.B. Ensemble d'anticorps monoclonaux diriges contre la lactoferrine humaine et le lysozyme humain
WO2003001205A1 (en) * 2001-06-25 2003-01-03 Pharmacia Diagnostics Ab Method for estimation of the amount of specific cell types
CN108226016A (zh) * 2018-01-12 2018-06-29 浙江普罗亭健康科技有限公司 肿瘤免疫细胞亚群精准分型的质谱流式检测试剂盒
WO2019108554A1 (en) * 2017-11-28 2019-06-06 The Board Of Trustees Of The Leland Stanford Junior University Cellular morphometry methods and compositions for practicing the same
CN110730789A (zh) * 2017-06-16 2020-01-24 阿根思公司 抗cd70抗体argx-110用于治疗急性骨髓性白血病的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10114012B2 (en) * 2008-10-31 2018-10-30 The Board Of Trustees Of The Leland Stanford Junior University Methods and assays for detecting and quantifying pure subpopulations of white blood cells in immune system disorders
WO2012134813A1 (en) * 2011-03-31 2012-10-04 St. Jude Children's Research Hospital Methods and compositions for identifying minimal residual disease in acute lymphoblastic leukemia
WO2012142411A1 (en) * 2011-04-15 2012-10-18 Clavis Pharma Asa Systems and methods for detecting hent1 expression in hematological disorders
EP3876955A4 (en) * 2018-11-09 2022-08-24 Pierian Biosciences, LLC METHODS AND COMPOSITIONS FOR DETERMINING THE COMPOSITION OF A TUMOR MICROENVIRONMENT
WO2020107496A1 (zh) * 2018-12-01 2020-06-04 铭道创新（北京）医疗技术有限公司 一种免疫细胞中淋巴细胞的流式细胞仪检测方法
CN110412287A (zh) * 2019-07-11 2019-11-05 上海宸安生物科技有限公司 一种基于单细胞的免疫细胞分型定量分析方法
NL2024163B1 (en) * 2019-11-05 2021-07-20 Univ Of Salamanca Means and methods for multiparameter cytometry-based leukocyte subsetting.
CN112147326B (zh) * 2020-09-04 2022-04-08 北京大学 一种肿瘤免疫细胞亚群分型精准检测试剂盒
CN113125754A (zh) * 2021-04-16 2021-07-16 浙江普罗亭健康科技有限公司 一种用于监测人体免疫状态的23抗体试剂盒及应用
CN113777327B (zh) * 2021-09-13 2022-09-02 北京大学人民医院 用于白血病/淋巴瘤免疫分型初筛的抗体组合物及其应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0181851A1 (fr) * 1984-10-10 1986-05-21 S.A. Laboratoires S.M.B. Ensemble d'anticorps monoclonaux diriges contre la lactoferrine humaine et le lysozyme humain
WO2003001205A1 (en) * 2001-06-25 2003-01-03 Pharmacia Diagnostics Ab Method for estimation of the amount of specific cell types
CN110730789A (zh) * 2017-06-16 2020-01-24 阿根思公司 抗cd70抗体argx-110用于治疗急性骨髓性白血病的用途
WO2019108554A1 (en) * 2017-11-28 2019-06-06 The Board Of Trustees Of The Leland Stanford Junior University Cellular morphometry methods and compositions for practicing the same
CN108226016A (zh) * 2018-01-12 2018-06-29 浙江普罗亭健康科技有限公司 肿瘤免疫细胞亚群精准分型的质谱流式检测试剂盒

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
F R DAVEY, S OLSON, A S KUREC, R EASTMAN-ABAYA, A J GOTTLIEB, D Y MASON: "The immunophenotyping of extramedullary myeloid cell tumors in paraffin-embedded tissue sections", AMERICAN JOURNAL OF SURGICAL PATHOLOGY., RAVEN PRESS, NEW YORK, NY., US, vol. 12, no. 9, 1 September 1988 (1988-09-01), US , pages 699 - 707, XP009549407, ISSN: 0147-5185, DOI: 10.1097/00000478-198809000-00006 *
XIA, CHENGQING ET AL.: "Application of Llow Cytometry in the Differential Diagnosis of Lymphoma/leukemia with Aberrant Antigen Expression", CHINESE JOURNAL OF PATHOLOGY, vol. 33, no. 6, 31 December 2004 (2004-12-31), pages 533 - 535, XP009549405 *

Also Published As

Publication number Publication date
CN114720358A (zh) 2022-07-08
EP4261220A1 (en) 2023-10-18
JP2023155889A (ja) 2023-10-23
US20230324395A1 (en) 2023-10-12
CN114720358B (zh) 2022-09-27
JP7388787B2 (ja) 2023-11-29

Similar Documents

Publication Publication Date Title
Fujimoto et al. Flow cytometric method for enumeration and classification of reactive immature granulocyte populations
Al-Mawali et al. Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry
Gong et al. Value of CD23 determination by flow cytometry in differentiating mantle cell lymphoma from chronic lymphocytic leukemia/small lymphocytic lymphoma
CN113777327B (zh) 用于白血病/淋巴瘤免疫分型初筛的抗体组合物及其应用
Kraan et al. Flow cytometric immunophenotyping of cerebrospinal fluid
CN112552407B (zh) 抗体组合物及其在检测急性b淋巴细胞白血病中的应用
CN114460311B (zh) 用于b-all/lbl免疫分型的试剂组合物及其应用
WO2007131507A2 (en) Methods for flow cytometry analyses of cells without lysing subpopulations
WO2023197182A1 (zh) 一种质谱流式血液肿瘤免疫分型中替代侧向散射光信号的抗体组合及应用
EP1363126B1 (en) Multidimensional leukocyte differential analysis
US11953500B2 (en) Detection reagent and therapeutic target for B cell tumor after targeted therapy and related application
Bayly et al. Validation of a modified pre‐lysis sample preparation technique for flow cytometric minimal residual disease assessment in multiple myeloma, chronic lymphocytic leukemia, and B‐non Hodgkin lymphoma
WO2005085842A2 (en) Method for the simultaneous detection of populations of several different biological entities using flow cytometry, device and computer program therefor
Chen et al. Immunophenotyping by multiparameter flow cytometry
Szánthó et al. Evaluation of sample quality as preanalytical error in flow cytometry analysis in childhood acute lymphoblastic leukemia
CN111537735A (zh) 抗体检测试剂盒以及在免疫分析方面的应用
Wu et al. The usefulness of CD71 expression by flow cytometry for differentiating indolent from aggressive CD10+ B-cell lymphomas
Park et al. Development of a novel flow cytometry-based system for white blood cell differential counts: 10-color LeukoDiff
Kim et al. Subtyping lymphocytes in peripheral blood by immunoperoxidase labeling and light scatter/absorption flow cytometry.
CN115290875A (zh) 一种6色tbnk淋巴细胞亚群检测试剂盒和检测方法
Nguyen et al. Myeloperoxidase detection by three-color flow cytometry and by enzyme cytochemistry in the classification of acute leukemia
US20040110122A1 (en) Three-color reagent for measurement of CD4 positive lymphocytes by flow cytometry
Bibawi Automated Database and Pattern-guided Immunophenotypic Classification of Acute Leukaemia Using Next Generation Flow Cytometry
Park DongJin et al. Development of a novel flow cytometry-based system for white blood cell differential counts: 10-color LeukoDiff.
JP2005221323A (ja) 骨髄異形成症候群の検出方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22936836

Country of ref document: EP

Kind code of ref document: A1